Cargando…

Spironolactone in pulmonary arterial hypertension: results of a cross-over study

The renin–angiotensin–aldosterone system is implicated in the pathophysiology of pulmonary arterial hypertension. We undertook this study to determine the effects of spironolactone, a mineralocorticoid receptor blocker, on collagen metabolism in pulmonary arterial hypertension patients. After obtain...

Descripción completa

Detalles Bibliográficos
Autores principales:	Safdar, Zeenat, Frost, Adaani, Basant, Arya, Deswal, Anita, O’Brian Smith, E., Entman, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219009/ https://www.ncbi.nlm.nih.gov/pubmed/32426108 http://dx.doi.org/10.1177/2045894019898030

Ejemplares similares

Effect of spironolactone use in pulmonary arterial hypertension – analysis from pivotal trial databases
por: Safdar, Zeenat, et al.
Publicado: (2021)

Longitudinal change in pulmonary arterial capacitance as an indicator of prognosis and response to therapy and in pulmonary arterial hypertension
por: Medrek, Sarah K., et al.
Publicado: (2017)

A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance
por: Ramasubbu, Kumudha, et al.
Publicado: (2010)

Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension
por: Safdar, Zeenat
Publicado: (2011)

Goiter in a Patient with Pulmonary Arterial Hypertension Treated with Epoprostenol
por: Abughazaleh, Shaadi, et al.
Publicado: (2020)

Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
por: Oriaku, Ifeoma, et al.
Publicado: (2020)

Update on pulmonary hypertension complicating chronic obstructive pulmonary disease
por: Jyothula, Soma, et al.
Publicado: (2009)

Use of Extracorporeal Membrane Oxygenation in Postpartum Management of a Patient with Pulmonary Arterial Hypertension
por: Abid Memon, Humna, et al.
Publicado: (2018)

Chronic Thromboembolic Pulmonary Hypertension Medical Management
por: Logue, Ryan, et al.
Publicado: (2021)

A novel BMPR2 mutation with widely disparate heritable pulmonary arterial hypertension clinical phenotype
por: Oriaku, Ifeoma, et al.
Publicado: (2020)

Association of spironolactone treatment and arterial stiffness and cardiovascular disease in hypertensive patients
por: Zeng, Fanfang, et al.
Publicado: (2019)

Diagnosis of pulmonary hypertension
por: Frost, Adaani, et al.
Publicado: (2019)

Risk stratification and medical therapy of pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2019)

Effect of Spironolactone on Diabetic Nephropathy Compared to the Combination of Spironolactone and Losartan
por: Makhlough, Atieh, et al.
Publicado: (2014)

A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care
por: Lee, Joshua D., et al.
Publicado: (2020)

Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension
por: White, R. James, et al.
Publicado: (2019)

A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial
por: Elinoff, Jason M, et al.
Publicado: (2013)

The echocardiographic course of pretransplant pulmonary hypertension following kidney transplantation and associated outcomes
por: Frost, Adaani E., et al.
Publicado: (2022)

Effect of Spironolactone in Resistant Arterial Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial (ASPIRANT-EXT)
por: Václavík, Jan, et al.
Publicado: (2014)

Modification of ventriculo–arterial coupling by spironolactone in nonischemic dilated cardiomyopathy
por: Lawson, Mark A., et al.
Publicado: (2021)

Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension
por: Bourge, Robert C, et al.
Publicado: (2013)

Computed axial tomography evidence of left atrial enlargement: a predictor of elevated pulmonary capillary wedge pressure in pulmonary hypertension
por: Safdar, Z, et al.
Publicado: (2010)

Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension
por: Vizza, Carmine Dario, et al.
Publicado: (2017)

Effects of spironolactone in spontaneously hypertensive adult rats subjected to high salt intake
por: Baldo, Marcelo Perim, et al.
Publicado: (2011)

Spironolactone-Induced Unilateral Gynecomastia
por: Veeregowda, Sahana Hadihalli, et al.
Publicado: (2018)

The evolution of survival of pulmonary arterial hypertension over 15 years
por: Hendriks, Paul M., et al.
Publicado: (2022)

Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat
por: Leader, Catherine J., et al.
Publicado: (2020)

Spironolactone Reduces Aortic Stiffness in Patients With Resistant Hypertension Independent of Blood Pressure Change
por: Aryal, Sudeep R., et al.
Publicado: (2021)

Association between Use of Spironolactone and Risk of Stroke in Hypertensive Patients: A Cohort Study
por: Cai, Xintian, et al.
Publicado: (2022)

Does the aldosterone: renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study
por: Parthasarathy, Hari K, et al.
Publicado: (2007)

Management of Pulmonary Artery Aneurysms in Pulmonary Hypertension: A Single-Center Review of 3 Cases
por: Ahmed, Talha, et al.
Publicado: (2019)

Effect of spironolactone on pain responses in mice
por: Abdel-Salam, Omar M.E., et al.
Publicado: (2010)

Spironolactone in cardiovascular disease: an expanding universe?
por: Funder, John W.
Publicado: (2017)

Imatinib and spironolactone suppress hepcidin expression
por: Mleczko-Sanecka, Katarzyna, et al.
Publicado: (2017)

Furosemide/spironolactone: Hypotension: case report
Publicado: (2022)

Topical Spironolactone in the Treatment of Evaporative Dry Eye Disease
por: Wong, Calvin W, et al.
Publicado: (2023)

Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study – a randomized controlled trial
por: Oliveras, Anna, et al.
Publicado: (2016)

Spironolactone Reduces Severity of Obstructive Sleep Apnea in Patients with Resistant Hypertension: a Preliminary Report
por: Gaddam, Krishna, et al.
Publicado: (2009)

Clinical efficacy and safety of spironolactone in patients with resistant hypertension: A systematic review and meta-analysis
por: Chen, Cong, et al.
Publicado: (2020)

Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension
por: Tsujimoto, Tetsuro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e203pbce9fofmo6sh754pchvf7